NLM

Agenus Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Health, Oncology, OS, BOT, Colitis, Inc., Colorectal cancer, PD, RECIST, IST, Partnership, RAS, Patient, MSI, FOLFIRINOX, BMS, Melanoma, MSS, BAL, Cancer, CRC, NLM, TIGIT, Liver disease, Pharmaceutical industry

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.

Key Points: 
  • Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.
  • “In 2023, Agenus made significant advances across our BOT/BAL development program.
  • $25 million milestone payment from BMS triggered by the commencement of a Phase 2 study with BMS-986442 in December 2023.
  • For the fourth quarter ended December 31, 2023, we recognized revenue of $84 million and incurred a net loss of $49 million or $0.13 per share.

AZTEQ Metaverse Unveils "Life" - An Ultra High Capacity Metaverse On WebGPU

Retrieved on: 
Tuesday, December 12, 2023
Metaverse, Tetra, Rosmalen, NLM, Work, XT, Modding, Friends, Cryptocurrency and crime, Decentralized finance, Holiday, Happiness, XR, Web browser, Fail-safe, Intelligence, Lossless compression, WebGPU, Immersion, Onyx, Environment, Video game

Life promises to be a game-changer in the metaverse landscape, driven by AZTEQ's flagship technologies, Tetra and Avenge.

Key Points: 
  • Life promises to be a game-changer in the metaverse landscape, driven by AZTEQ's flagship technologies, Tetra and Avenge.
  • It's the ultimate metaverse, designed to revolutionize the way we live, work, and play.
  • This game engine, Tetra, leverages Web3 and harnesses the full power of WebGPU to deliver an unmatched gaming experience.
  • AZTEQ Metaverse is no stranger to blockchain innovation, Avenge, their in-house developed top layer blockchain, exemplifies this by being the backbone of their metaverse.

AZTEQ Metaverse Unveils "Life" - A Ultra High Capacity Metaverse On WebGPU

Retrieved on: 
Tuesday, December 12, 2023
Metaverse, Tetra, Rosmalen, NLM, Work, XT, Modding, Friends, Cryptocurrency and crime, Decentralized finance, Holiday, Happiness, XR, Web browser, Fail-safe, Intelligence, Lossless compression, WebGPU, Immersion, Onyx, Environment, Video game

Life promises to be a game-changer in the metaverse landscape, driven by AZTEQ's flagship technologies, Tetra and Avenge.

Key Points: 
  • Life promises to be a game-changer in the metaverse landscape, driven by AZTEQ's flagship technologies, Tetra and Avenge.
  • Unlike anything experienced before, Life offers a boundless, immersive world where people can connect, create, and explore like never before.
  • This game engine, Tetra, leverages Web3 and harnesses the full power of WebGPU to deliver an unmatched gaming experience.
  • AZTEQ Metaverse is no stranger to blockchain innovation, Avenge, their in-house developed top layer blockchain, exemplifies this by being the backbone of their metaverse.

NIH Selects ICF for $31 Million in Biomedical and Digital Modernization Work

Retrieved on: 
Wednesday, November 1, 2023
ICFI, Epidemiology, National library, Health, United States National Library of Medicine, Human services, BPA, Maintenance, Data management, ClinicalTrials.gov, Caregiver, ICF, NLM, NIH, Public, Office of Inspector General, U.S. Department of Health and Human Services, Patient, Bangladesh Technical Education Board, Nursing

RESTON, Va., Nov. 1, 2023 /PRNewswire/ -- The National Institutes of Health (NIH) National Library of Medicine (NLM) recently awarded global consulting and technology services provider ICF (NASDAQ:ICFI) two agreements with a combined value of $31 million to provide biomedical and technical expertise, as well as data management and digital modernization services.

Key Points: 
  • The first agreement is a new multiple-award blanket purchase agreement (BPA) to collect, curate, and enhance access to critical biomedical and public health data.
  • ICF's efforts will improve data delivery to health researchers, professionals and the public so vital health decisions can quickly be made.
  • ICF has also been awarded five new task orders under the BPA with a combined value of $4 million to provide health expertise, systems maintenance and long-range planning support.
  • The second agreement is an 18-month, $27 million recompete contract for the operation, maintenance and modernization of ClinicalTrials.gov, a project ICF has supported since 2009.

Geneial Receives New NIH Grant For Private Pharmacogenomics Workflow

Retrieved on: 
Wednesday, November 1, 2023
Research, Whole genome sequencing, Genomics, National library, Health, Life, SBIR, Multimedia, Genome, NLM, Association of British HealthTech Industries, WGS, Privacy, NIH, Bangladesh Technical Education Board, Pharmaceutical industry, Medical imaging, Medicine

HOUSTON, Nov. 1, 2023 /PRNewswire/ -- Geneial, the HealthTech startup, continues its work to address the challenges of balancing privacy and data ownership interests with making genomic data more available for research and clinical settings. After recently announcing the launch of a platform for Rare Disease registries, such as the Xia-Gibbs Syndrome Registry, this new grant from the NIH National Library of Medicine (NLM) will enable the expansion of Geneial platform capabilities to address barriers facing the widespread clinical implementation of pharmacogenomics (PGx).

Key Points: 
  • After recently announcing the launch of a platform for Rare Disease registries , such as the Xia-Gibbs Syndrome Registry, this new grant from the NIH National Library of Medicine (NLM) will enable the expansion of Geneial platform capabilities to address barriers facing the widespread clinical implementation of pharmacogenomics (PGx).
  • Geneial was awarded an NIH grant to expand its privacy-preserving genetic data platform into pharmacogenomics.
  • PGx promises to optimize drug dosage while minimizing adverse effects, enabling accurate decisions about treatment courses.
  • To address these concerns, Geneial aims to allow individuals to maintain ownership and transactional-level control over the use of their existing whole genome sequencing (WGS) data.

Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

Retrieved on: 
Wednesday, September 20, 2023
Atezolizumab, Diabetes, Neoplasm, Doctor of Philosophy, ODA, National library, Patient, GC, Disease, Prostate cancer, Carcinoma, CD47, Hope, Research, ACHL, Lung cancer, NLM, Orphan drug, Death, Drug development, Diagnosis, Growth, Rare, FDA, Legislation, Civil service commission, ODD, Roche, Orphan Drug Act of 1983, PharmaMar, Cancer, NSCLC, Treatment of lung cancer, ES, Therapy, Stomach, ORR, European Commission, File, United States National Library of Medicine, MedImmune, Inc. v. Genentech, Inc., Clinical trial, Woman, Lung, Fast track (FDA), SCLC, American Cancer Society, Achilles, Melanoma, OTCQX, Orphan, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FTD, RET, Food, Breast cancer, Pharmaceutical industry, Medical imaging, Genentech, Pembrolizumab

NEW YORK, Sept. 20, 2023 /PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation of new treatments, particularly for rare diseases, is a key priority for the U.S. Food & Drug Administration. As part of that process, the agency can grant Orphan Drug Designation (ODD) to a drug or biological product being developed to prevent, diagnose or treat a rare disease or condition. This designation is intended to spark innovation among biotech companies that are developing treatments for these patient populations, which by definition affect fewer than 200,000 people in the U.S., by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. Last month, Genprex Inc. (NASDAQ: GNPX) (Profile) was granted FDA orphan drug designation for its REQORSA(R) immunogene therapy in development for the treatment of small cell lung cancer (SCLC). The Phase 1/2 clinical trial, expected to dose the first patient in the fourth quarter of 2023, uses a combination of REQORSA and Genentech Inc.'s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer ("ES-SCLC") who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Genprex joins other companies — including Roche Holding AG ADR (OTCQX: RHHBY), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), ALX Oncology Holdings Inc. (NASDAQ: ALXO) and Achilles Therapeutics PLC (NASDAQ: ACHL) — that have been granted ODD status or may seek ODD status as they work to develop treatments for rare diseases.

Key Points: 
  • Four decades after the Orphan Drug Act was passed, hundreds of 'orphan' drugs have been approved for use.
  • Genprex's REQORSA Immunogene Therapy has gained both Orphan Drug Designation and Fast Track Designation.
  • Specifically, the report noted that 6,340 orphan drug designations were granted, representing drug development for 1,079 rare diseases.
  • For companies looking to help those in the underserved rare-disease space, an Orphan Drug Designation is the ideal pathway to progress.

Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

Retrieved on: 
Wednesday, September 20, 2023
Atezolizumab, Diabetes, Neoplasm, Doctor of Philosophy, ODA, National library, Patient, GC, Disease, Prostate cancer, Carcinoma, CD47, Hope, Research, ACHL, Lung cancer, NLM, Orphan drug, Death, Drug development, Diagnosis, Growth, Rare, FDA, Legislation, Civil service commission, ODD, Roche, Orphan Drug Act of 1983, PharmaMar, Cancer, NSCLC, Treatment of lung cancer, ES, Therapy, Stomach, ORR, European Commission, File, United States National Library of Medicine, MedImmune, Inc. v. Genentech, Inc., Clinical trial, Woman, Lung, Fast track (FDA), SCLC, American Cancer Society, Achilles, Melanoma, OTCQX, Orphan, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FTD, RET, Food, Breast cancer, Pharmaceutical industry, Medical imaging, Genentech, Pembrolizumab

NEW YORK, Sept. 20, 2023 /PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation of new treatments, particularly for rare diseases, is a key priority for the U.S. Food & Drug Administration. As part of that process, the agency can grant Orphan Drug Designation (ODD) to a drug or biological product being developed to prevent, diagnose or treat a rare disease or condition. This designation is intended to spark innovation among biotech companies that are developing treatments for these patient populations, which by definition affect fewer than 200,000 people in the U.S., by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. Last month, Genprex Inc. (NASDAQ: GNPX) (Profile) was granted FDA orphan drug designation for its REQORSA(R) immunogene therapy in development for the treatment of small cell lung cancer (SCLC). The Phase 1/2 clinical trial, expected to dose the first patient in the fourth quarter of 2023, uses a combination of REQORSA and Genentech Inc.'s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer ("ES-SCLC") who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Genprex joins other companies — including Roche Holding AG ADR (OTCQX: RHHBY), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), ALX Oncology Holdings Inc. (NASDAQ: ALXO) and Achilles Therapeutics PLC (NASDAQ: ACHL) — that have been granted ODD status or may seek ODD status as they work to develop treatments for rare diseases.

Key Points: 
  • Four decades after the Orphan Drug Act was passed, hundreds of 'orphan' drugs have been approved for use.
  • Genprex's REQORSA Immunogene Therapy has gained both Orphan Drug Designation and Fast Track Designation.
  • Specifically, the report noted that 6,340 orphan drug designations were granted, representing drug development for 1,079 rare diseases.
  • For companies looking to help those in the underserved rare-disease space, an Orphan Drug Designation is the ideal pathway to progress.

Lung Cancer Research Foundation (LCRF) Joins Carebox Connect Network

Retrieved on: 
Tuesday, August 1, 2023
United States National Library of Medicine, Clinical trial, Lung cancer, Research, Bangladesh Technical Education Board, Organization, NLM, National library, Patient, Diagnosis, NIH, Caregiver, Medical imaging, Online shopping

NEW YORK and RALEIGH, N.C., Aug. 1, 2023 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) and Carebox, a leading provider of clinical trial matching solutions, today announced the launch of a Carebox Connect experience optimized for lung cancer patients.

Key Points: 
  • Carebox to help LCRF advance lung cancer research by making it easier and more effective for patients, caregivers, and healthcare professionals to identify relevant lung cancer trials.
  • NEW YORK and RALEIGH, N.C., Aug. 1, 2023 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) and Carebox, a leading provider of clinical trial matching solutions, today announced the launch of a Carebox Connect experience optimized for lung cancer patients.
  • "LCRF is on a mission to improve lung cancer outcomes by funding research for prevention, diagnosis, treatment, and cure.
  • "The Carebox Connect Network has a common technology foundation and a unified end-user application," notes Assaf Levi, Carebox VP of R&D.

MediKarma Introduces JILL.ai - The Ultimate AI Personal Health Assistant

Retrieved on: 
Wednesday, June 7, 2023
Insurance, MIT Media Lab, Education, United States National Library of Medicine, VBC, Health, Human, Privacy, NLM, National library, Trust, SAN, AI, WHO, World Health Organization, Medical device, Mobile phone

SAN FRANCISCO, June 7, 2023 /PRNewswire/ -- MediKarma, an AI-based patient engagement, education and preventative care, today announced the launch of its generative-AI powered personalized health assistant, "JILL.ai." The offering is poised to elevate the current paradigm of preventative and value-based care (VBC) by delivering personalized healthcare guidance at scale, effectively democratizing information, and empowering users to take complete charge of their health.

Key Points: 
  • SAN FRANCISCO, June 7, 2023 /PRNewswire/ -- MediKarma , an AI-based patient engagement, education and preventative care, today announced the launch of its generative-AI powered personalized health assistant, "JILL.ai."
  • As a generative-AI powered personalized health assistant, JILL.ai can support users through a broad spectrum of health services, like instantly retrieving information from health records and devices, answering generic health questions, providing personalized recommendations, conducting self-symptom triage, explaining insurance and financial considerations, automating health routines such as appointment booking with doctors, and more.
  • JILL.ai's capabilities are delivered through interactive voice commands in natural language, making it a true, first-of-its-kind, human-like health assistant.
  • MediKarma is committed to trust and transparency in its AI development, which is reflected in the design of JILL.ai.

Treos Bio Announces Presentation of Final Results from Phase 1b Study of PolyPEPI1018 Immunotherapy for Late-Stage Metastatic Colorectal Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Monday, June 5, 2023
Antigen, Mayo Clinic, Liver disease, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Vaccination, MSS, OS, Clinical Cancer Research, Biomarker, Immunotherapy, PFS, PBMC, CD8, ELISA, ASCO, NLM, American Society of Clinical Oncology, Patient, Immunoglobulin G, LM, Annual general meeting, HR, Neoplasm, Research, MOS, Society, Safety, Data science, Pharmaceutical industry, Vaccine, Medical imaging, Palm Treo

PolyPEPI1018 is an off-the-shelf, multi-peptide vaccine derived from seven tumor associated antigens frequently expressed in patients with mCRC.

Key Points: 
  • PolyPEPI1018 is an off-the-shelf, multi-peptide vaccine derived from seven tumor associated antigens frequently expressed in patients with mCRC.
  • Final results from the study, conducted by Mayo Clinic in Minnesota, demonstrate that PolyPEPI1018 in combination with TAS-102 improved progression free-survival (PFS) and overall survival (OS) compared to historical data for standard of care TAS-102 alone.
  • “Importantly, these results show consistency between immunological responses and efficacy, and a particularly enhanced benefit in patients without liver metastasis.
  • Final results from the study demonstrate that PolyPEPI1018 and TAS-102 were safe and tolerable in combination with safety and toxicity profiles similar to TAS-102 monotherapy.